"her2 breast cancer" trang 4 - tải miễn phí từ tailieunhanh
Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer

Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer
15    63    1
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy
7    34    1
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
8    31    1
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study
7    56    3
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: A systematic review

Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: A systematic review
14    19    1
Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer

Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
13    1    1
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: A multicenter real-world study in the northwest of China

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: A multicenter real-world study in the northwest of China
13    6    1
Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression

Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression
9    3    1
PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials

PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials
11    1    1
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial
12    43    1
Combined analysis of PTEN, HER2, and hormone receptors status: Remodeling breast cancer risk profiling

Combined analysis of PTEN, HER2, and hormone receptors status: Remodeling breast cancer risk profiling
10    22    1
Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER2−metastatic or advanced breast cancer patients: A network meta-analysis

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER2−metastatic or advanced breast cancer patients: A network meta-analysis
12    1    1
The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer

The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer
10    54    0
Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database
11    52    1
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: Results of a pilot study

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: Results of a pilot study
10    36    1
In silico screening of alkaloids as potential inhibitors of HER2 protein for breast cancer treatment

In silico screening of alkaloids as potential inhibitors of HER2 protein for breast cancer treatment
10    6    1
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review
8    84    1
A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: An analytical and clinical validation study

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: An analytical and clinical validation study
15    70    1
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
14    62    1
báo cáo khoa học:

báo cáo khoa học: "Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer"
9    37    0